ArticleUltrasonography (Seoul, Korea)2026
Early ultrasound markers for predicting the transition from acute kidney injury to chronic kidney disease and treatment response in a murine model.
Article in Ultrasonography (Seoul, Korea), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeThis study evaluated the feasibility of ultrasound (US) parameters for predicting the transition from acute kidney injury (AKI) to chronic kidney disease (CKD) and assessing the therapeutic response to 17-DMAG, a fibrosis-mitigating agent, in a murine unilateral ischemia-reperfusion injury (UIRI) model.
methodsMale C57BL/6 mice were assigned to sham (n=16) or UIRI (n=24) groups, with half of the UIRI mice receiving 17-DMAG (20 mg/kg intraperitoneally, three times weekly). Serial US examinations were performed on postoperative days (PODs) 3 and 8 to evaluate morphological parameters (kidney size and parenchymal thickness [PT]), vascular parameters (resistive index [RI] and vascular index [VI] derived from microvascular imaging [MVI]), and tissue stiffness assessed by shear-wave speed (SWS). Pathologic fibrosis was defined as a Sirius red-positive area >4%. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curve analysis.
resultsAt the early stage (POD 3), vascular parameters (VI and RI) demonstrated high diagnostic performance for predicting fibrosis progression (area under the receiver operating characteristic curve, 0.948 and 0.890, respectively), with VI serving as the only significant predictor of early treatment response to 17-DMAG. At POD 8, all parameters showed significant diagnostic performance for predicting fibrosis progression. However, for treatment response, only kidney size, PT, and RI demonstrated significant ROC performance, whereas VI and SWS did not reach statistical significance. These findings reflect the temporal transition from early functional microvascular compromise to established structural remodeling and parenchymal atrophy.
conclusionRI and VI are promising noninvasive surrogate markers for predicting the AKI-to-CKD transition, and VI may be useful for assessing early responses to 17-DMAG treatment. Whereas conventional US parameters identify late-stage structural remodeling, MVI provides a critical diagnostic window during the acute phase by detecting early microvascular compromise. These findings highlight the potential utility of MVI for real-time monitoring of AKI progression and anti-fibrotic treatment responses in clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.